Detalhe da pesquisa
1.
Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.
Theranostics
; 14(1): 17-32, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164150
2.
Opposing effects of cannabidiol in patient-derived neuroendocrine tumor, pheochromocytoma/paraganglioma primary cultures.
J Clin Endocrinol Metab
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38605427
3.
PD-L1 and HIF-2α Upregulation in Head and Neck Paragangliomas after Embolization.
Cancers (Basel)
; 15(21)2023 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37958373
4.
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Eur J Endocrinol
; 189(5): 546-565, 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37949483
5.
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
J Clin Endocrinol Metab
; 108(10): 2676-2685, 2023 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36946182
6.
Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
Target Oncol
; 17(6): 683-694, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36136211